<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) progression is characterized by occurrence of new cytogenetic and molecular abnormalities </plain></SENT>
<SENT sid="1" pm="."><plain>In the previous study, we have shown the important role of GATA-2 L359 V mutation in <z:mp ids='MP_0005481'>CML</z:mp> progression </plain></SENT>
<SENT sid="2" pm="."><plain>To further ascertain the truth of transcription factor GATA-2 in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, we expanded our study to GATA-2 full length by directly sequencing and applied MassARRAY assay into GATA-2 L359 V mutation analysis </plain></SENT>
<SENT sid="3" pm="."><plain>Finally, no GATA-2 L359 V mutation was found in 270 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, 30 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, 50 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, 12 <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, 40 <z:mp ids='MP_0005481'>CML</z:mp> <z:hpo ids='HP_0011010'>chronic</z:hpo> phase and 286 BCR/ABL negative <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> except <z:mp ids='MP_0005481'>CML</z:mp> <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>A new variation of GATA-2 resulted in P250A change was identified, which was not found to have statistical difference between patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> and healthy control </plain></SENT>
<SENT sid="5" pm="."><plain>Hence, we concluded GATA-2 L359 V is exclusively associated with <z:mp ids='MP_0005481'>CML</z:mp> progression but not other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> and P250A is a new single nucleotide polymorphism </plain></SENT>
</text></document>